Blockchain Registration Transaction Record

Volition's Biomarker Chosen for French Sepsis Detection Program

VolitionRx's Nu.Q® H3.1 assay selected for France's DETECSEPS sepsis detection program, aiming to improve emergency care with rapid results and better outcomes.

This news matters because sepsis is a life-threatening condition that affects millions globally, with early detection being crucial for survival and reducing long-term health complications. The selection of Volition's Nu.Q® H3.1 assay for the DETECSEPS program could lead to faster, more accurate diagnosis in emergency settings, potentially saving lives and lowering healthcare costs. For patients, it means quicker access to treatment, improved recovery prospects, and better quality of life. For the healthcare industry, it represents an advancement in precision medicine, leveraging epigenetics to enhance diagnostic tools. This development highlights the growing role of innovative biomarkers in transforming patient care and addressing public health challenges like sepsis, which often has high mortality rates due to delayed intervention.